Ongoing Trials

Here you find a list of all ongoing trials in NMSG with a short description and contact details for the principal investigator of the study. All NMSG members have access to the full protocol at the member area.

NMSG 26/19 – TOP75+

Full study name: RWD Working Group NMSG: Treatment and Outcome in MM Patients 75 and above

Principal investigator: Cecilie Hveding Bilmark

Type of study: Register study

Number of patients: 3000

Sites including patients: Denmark and Sweden

Synopsis: Not available yet

NMSG 27/19 – NOR-ASCT

Full study name: ASCT-Treatment in Nordic and Baltic MM Patients

Principal investigator: Cecilie Hveding Bilmark

Type of study: Register Study,

Number of patients: 2500

Sites including patients: NMSG countries

Synopsis: Not available yet

NMSG 25/16 - The CONPET study

KRd consolidation in myeloma patients with apositive PET-CT after standard first line treatment. A phase II study

Principal investigator: Fredrik Schjesvold

Type of study: Phase 2

Number of patients: 50

Sites including patients: Oslo, Odense, Bergen, Vejle, København, Lisboa

Click me for Synopsis

NMSG 23/15

Principal investigator: Raija Silvennoinen

Type of study: Phase II

Number of patients: 120

Sites including patients:

  •  Finland: Helsinki, Turku, Tampere, Oulu, Kuopio, Kotka, Jyväskylä, Kajaani, Lahti

  •  Norway: Trondheim, Oslo, Stavanger, Förde

  •  Sweden: Stockholm, Lund, Uppsala, Göteborg, Örebro, Linköping, Sunderby Luleå, Helsingborg, Borås, Varberg, Uddevalla, Halmstad

  •  Lithuanian: Vilnius

Click me for Synopsis

NMSG 22/14  The Magnolia Study

Prolonged Protection from Bone Disease in Multiple Myeloma. An open label phase 4 multicenter international randomised trial

Principal investigator: Thomas Lund

Type of study: Phase IV prospective randomised multicentre open-label study.

Number of patients: 358

Click me for Synopsis

NMSG 20/13 - CARFI

A phase 2 study of carfilzomib-cyclophosphamide-dexamethasone and high-dose melphalan followed by randomization between observation or maintenance with carfil-zomib and dexamethasone in patients with relapsed multiple myeloma after high-dose melphalan with autologous stem cell support Principal investigator: Henrik Gregersen Type of study: Phase II Number of patients: 200 Sites including patients:

o Denmark: Aalborg, Aarhus, Herlev, Odense, Rigshospitalet, Roskilde.

o Finland: Kuopio, Oulu, Tampere, Turku.

o Norway: Oslo, Kristiansand. Trondheim

o Sweden: Helsingborg, Karolinska, Linköping, Lund, Sahlgrenska, Sunderbyn, Uddevalla, Umeå, Uppsala, Örebro.

o Lithuania: Vilnius

Click me for Synopsis

Status: Closed

HOVON 129/EMN 12 (collaborative study)

Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnoses primary plasma cell leukemia patients.:

Principal investigator NMSG: Annette Vangsted

Type of study: Phase II, prospective, multicenter, intergroup

Number of patients: 116 Sites including patients in NMSG: Denmark (Aarhus, Odense, Rigshospitalet), Norway (Oslo and Trondheim)

Hovon 95/EMN (collaborative study)

A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple

Principal investigator: Dr. P. Sonneveld

Type of study: Phase III randomized.

Number of patients: 1500

Sites including patients: See synopsis

Click me for Synopsis

Status: Closed

Hovon 126 (collaborative study)

Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trial

Principal investigator: S. Zweegman (HOVON), N. Abildgaard (NMSG)

Type of study: Phase II

Number of patients: 142

Former and finalized studies

The NMSG has conducted 12 clinical trials the past 10 years. Here you find a list of the trials including a link to the main publication. In addition there are many spin-off studies based on these clinical trials.

  • MP-T + Thal maintenance vs. MP-R + Rev maintenance as first line treatment in elderly newly diagnosed (phase III, NMSG-HOVON-study)

Publications:

  1. Zweegman et al, Blood. 2016 Mar 3;127(9):1109-16 [https://www.ncbi.nlm.nih.gov/pubmed/26802176]

  • NOP in refractory myeloma (phase II) and newly diagnosed myeloma (phase III)

Publications:

  1. Gimsing et al. Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG). Br J Haematol. 1991 Jan;77(1):73-9.

  2. Wisløff et al. Bolus therapy with mitoxantrone and vincristine in combination with high-dose prednisone (NOP-bolus) in resistant multiple myeloma. Nordic Myeloma Study Group (NMSG). Eur J Haematol. 1992 Feb;48(2):70-4.

  3. Keldsen et al. Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG).Eur J Haematol. 1993 Aug;51(2):80-5.

  • MP vs. MP+IFNa (phase III)

Publications: 

  1. Wisløff F, et al.Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1996 Mar;92(3):604-13. DOI:10.1046/j.1365-2141.1996.352889.x

  2. Wisløff F, et al.Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. Br J Haematol. 1996 Aug;94(2):324-32. DOI:10.1046/j.1365-2141.1996.d01-1802.x

  3. Wisløff et al. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1997 Apr;97(1):29-37. DOI: 10.1046/j.1365-2141.1997.222667.x

  • High-dose chemotherapy + stem cell support in patients < 60 years (vs. historical control)

Publications:

  1. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000 Jan 1;95(1):7-11.

  2. Lenhoff S, Hjorth M, Westin J, Brinch L, Backstrom B, Carlson K, et al. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006 May;133(4):389-96. DOI: 10.1111/j.1365-2141.2006.06042.x

  • High-dose chemotherapy + stem cell support in patients < 65 years (vs. historical control)

Publications: 

  1. Mellqvist et al, Cancer. 2008 Jan 1;112(1):129-35. [https://www.ncbi.nlm.nih.gov/pubmed/17973267]

  • Induction chemotherapy VAD vs. Cy-Dex (phase III)

Publications:​

  1. Mellqvist et al, Cancer. 2008 Jan 1;112(1):129-35. [https://www.ncbi.nlm.nih.gov/pubmed/17973267]

  • Induction chemotherapy Cy-Fludarabin-Dex vs. Cy-Dex (phase II)

Publications:​

  1. HE Johnsen, LM Knudsen, AK Mylin, P Gimsing, H Gregersen, N Abildgaard, JL Nielsen, N Frost Andersen, T Plesner, A Vangsted, T Mourits-Andersen. Impaired stem cell mobilization by adding fludarabine to cyclophophamide-dexamethason induction therapy in multiple myeloma patients. Report from the NMSG #13/03 sponsored randomized, placebo controlled trial. Hematology Reviews, vol 1; 62-64. 2009

  • MP vs. MP-T in elderly newly diagnosed (phase III)

Publications:

  1. Waage et al, Blood. 2010 Sep 2;116(9):1405-12 [https://www.ncbi.nlm.nih.gov/pubmed/20448107]

  •  Pamidronate 90 mg vs. 30 mg in bone protection (phase III)

Publications:

  1. Gimsing et al Lancet Oncol. 2010 Oct;11(10):973-82 [https://www.ncbi.nlm.nih.gov/pubmed/20863761]

  • Bortezomib-Dex vs. Thalidomide-Dex in first relapse (phase III)

Publications:

  1. Hjorth et al, Eur J Haematol. 2012 Jun;88(6):485-96. [https://www.ncbi.nlm.nih.gov/pubmed/22404182]

  • Bortezomib consolidation vs. no consolidation post-ASCT (phase III)

Publications:

  1. Mellqvist et al, Blood. 2013 Jun 6;121(23):4647-54. [https://www.ncbi.nlm.nih.gov/pubmed/23616624]

  • Bortezomib-Dex re-induction followed by Bortezomib+Melfalan conditioning and ASCT in first relaps after prior ASCT (phase II)

Publications:

  1. Gimsing et al, Bone Marrow Transplant. 2015 Oct; 50(10): 1306–1311 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598614/]

This website is a presentation of myeloma and the NMSG. The content of the website is for information exclusively. The information given on this site is not meant to and cannot replace professional counseling or treatment by a doctor. The information is not to be used for diagnosing or determining a treatment.

NMSG does not guarantee for the correctness of information of this website or websites to which referrals are made. NMSG cannot be held responsible neither directly nor indirectly for any damage or loss caused by your or a third party´s use or misuse of the website. All rights to the website and to material on the website belong to NMSG. This also applies to all written entries sent to the website. Entries, which are sent to the website, become the property of NMSG and may without limitation be used by NMSG and are treated without confidence. Any dispute that may arise regarding this website or as a consequence of using this website is to be settled according to Danish Law. NMSG is not responsible for direct, random, consequently indirect or criminal damages which may occur due to the access to or the use of the content on this website, including computer viruses, regardless of the accurateness or completeness.